Liraglutide Significantly Reduces Systolic Blood Pressure and Improves Renal Function in Type 2 Diabetic Nephropathy

Patients with Type 2 Diabetic Nephropathy (T2DN) face progressive kidney damage, a major complication of Type 2 Diabetes. Current standard-of-care often struggles to halt disease progression, with persistent hypertension and declining renal function being key challenges. GLP-1 receptor agonists like liraglutide are known for their glycemic benefits, but their direct impact on blood pressure and renal outcomes in T2DN has been less clear, prompting investigation into their potential pleiotropic effects beyond glucose control.

Written by TitrateLab, separately from the study summarized above.